Loading clinical trials...
Loading clinical trials...
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)
Conditions
Interventions
Balstilimab (BAL)
Topotecan
+4 more
Locations
3
United States
Optimum Research (Southwest Women's Oncology Center)
Albuquerque, New Mexico, United States
Hematology Center after prof. R. Yeolyan
Yerevan, Armenia
National Center of Oncology named after V.A. Fanarjian
Yerevan, Armenia
Start Date
August 2, 2021
Primary Completion Date
October 22, 2021
Completion Date
October 22, 2021
Last Updated
October 5, 2022
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Agenus Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions